Literature DB >> 25855929

RLN2 regulates in vitro invasion and viability of osteosarcoma MG-63 cells via S100A4/MMP-9 signal.

X-F Ren1, H Zhao, X-C Gong, L-N Wang, J-F Ma.   

Abstract

OBJECTIVE: Relaxin-2 (RLN2) increases cell migration, invasiveness and proliferation in vitro of osteosarcoma cells, but the molecular mechanisms of this action are still unknown. In the present study, we identified S100A4 /MMP-9 signaling as a major mediator of the actions of RLN2 in osteosarcoma cells in vitro.
MATERIALS AND METHODS: We have established stable transfectants of osteosarcoma MG-63 cells using small interfering RNA (siRNA) targeting RLN2. The stable transfectants (MG-63/RLN2 siRNA cells) were treated with 20 mM BB94 (a kind of MMP-9 activator) or 100 mM recombinant Human RLN2 (B-29/A-24) for 24 hs or transfected with S100A4 cDNA plasmid for 48 hrs or MMP-9 siRNA for 48 hrs then treated 100 mM recombinant Human RLN2 (B-29/A-24). Western blot assay was used to detect RLN2, S100A4 and MMP-9 expression. Matrigel invasion assay and wound healing assay was used to detect invasion in vitro. MTT was used to detect cell viability.
RESULTS: Knockdown of RLN2 using small interfering RNA decreases S100A4 and MMP-9 expression and inhibits invasion and cell viability in vitro. in MG-63 cells. Treatment with 100 mM recombinant Human RLN2 (B-29/A-24) for 24 hrs in MG-63/ RLN2 siRNA cells increases S100A4 and MMP-9 expression, and increases the invasion and cell viability in vitro in MG-63 cells. Transfection with S100A4 cDNA plasmid in MG-63/RLN2 siRNA cells for 48 hrs increases MMP-9 expression, and increase the invasion and cell viability of MG-63/RLN2 siRNA cells. Treatment with 20 mM BB94 (MMP-9 activator) for 24 hrs in MG-63/RLN2 siRNA cells increases MMP-9 expression, and increases the invasion and cell viability in vitro. in MG-63 cells.
CONCLUSIONS: Our results indicate that RLN2 regulats cell migration, invasiveness and proliferation of osteosarcoma cells in vitro, which may be mediated through S100A4/MMP-9 signaling.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25855929

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Development of a Novel Immune-Related Gene Signature to Predict Prognosis and Immunotherapeutic Efficiency in Gastric Cancer.

Authors:  Dongliang Liu; Yuanmin Xu; Yu Fang; Kongwang Hu
Journal:  Front Genet       Date:  2022-05-27       Impact factor: 4.772

2.  Expression of MMP-9/TIMP-2 in nasal polyps and its functional implications.

Authors:  Xuechang Li; Yanli Tao; Xuezhong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 3.  S100A4 in cancer progression and metastasis: A systematic review.

Authors:  Fei Fei; Jie Qu; Mingqing Zhang; Yuwei Li; Shiwu Zhang
Journal:  Oncotarget       Date:  2017-05-19

4.  Do Relaxin Levels Impact Hip Injury Incidence in Women? A Scoping Review.

Authors:  Emily A Parker; Alex M Meyer; Jessica E Goetz; Michael C Willey; Robert W Westermann
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-04       Impact factor: 5.555

5.  Novel CTRP8-RXFP1-JAK3-STAT3 axis promotes Cdc42-dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells.

Authors:  Aleksandra Glogowska; Thatchawan Thanasupawat; Jason Beiko; Marshall Pitz; Sabine Hombach-Klonisch; Thomas Klonisch
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.